| Bioactivity | Pipequaline (PK 8165) is a partial benzodiazepine receptor agonist with anxiolytic activity[1][2]. | ||||||||||||
| Target | Benzodiazepine receptor | ||||||||||||
| In Vivo | Intravenously administered pipequaline exerts a partial suppression of activations by kainate, glutamate and acetylcholine. Microiontophoretic applications of pipequaline reduces the neuronal activation by kainate[2]. Pipequaline produces dose-related decreases in motor activity. Pipequaline produces significant dose-related decreases in the number of head-dips made[3]. | ||||||||||||
| Name | Pipequaline | ||||||||||||
| CAS | 77472-98-1 | ||||||||||||
| Formula | C22H24N2 | ||||||||||||
| Molar Mass | 316.44 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Bradwejn J, et al. Effects of PK 8165, a partial benzodiazepine receptor agonist, on cholecystokinin-inducedactivation of hippocampal pyramidal neurons: a microiontophoretic study in the rat. Eur J Pharmacol. 1985 Jun 19;112(3):415-8. [2]. Debonnel G, et al. Pipequaline acts as a partial agonist of benzodiazepine receptors: an electrophysiological study in the hippocampus of the rat. Neuropharmacology. 1987 Sep;26(9):1337-42. |